Open AccessCancer Patients Have Necessary Been COVID-19 Vaccinated
Author(s) -
Attapon Cheepsattayakorn,
Ruangrong Cheepsattayakorn,
Porntep Siriwanarangsun
Publication year - 2021
Publication title -
trends in internal medicine
Language(s) - English
Resource type - Journals
ISSN - 2771-5906
DOI - 10.33425/2771-5906.1005
Subject(s) - immunogenicity , context (archaeology) , vaccination , covid-19 , medicine , malignancy , cancer , immune system , clinical trial , chemotherapy , immunotherapy , immunology , biology , paleontology , disease , infectious disease (medical specialty)
Hypothetically, mRNA-vaccine-encapsulated-small liposomes and lipid carriers may accumulate through the permeation retention and enhanced effect in tumor tissues. The recommendation that have been suggested administering COVID-19 vaccines one to two weeks prior to a chemotherapy dose by many key-professional organizations has not been practical with COVID-19 administration schedules (for examples; two doses of mRNA1273 (Moderna) are recommended to be given 28 days apart, whereas two doses of BNT162b2 (Pfizer/BioNTech) are given 21 days apart, efficacy > 94 %), variable chemotherapeutic regimens, and limited COVID-19 vaccination slot availability, contributing to allowing the most rapid COVID-19 vaccination of these immunosuppressed cancer patients and due to lacking COVID-19- vaccine safety and the information immunogenicity in the context of immune-system-stimulated immunotherapies (for examples; immune checkpoint inhibitor (ICI) therapy) and general exclusion of malignancy-diagnosed patients in the clinical trials of currently approved COVID-19 vaccines.